Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Gerlach, Jay ^a   Sequeira, Magda ^b   Alvarado, Vivian ^b   Cerpas, Christian ^c   Balmaseda, Angel ^c   Gonzalez, Alcides ^c   De Los Santos, Tala ^a   Levin, Carol E ^a   Amador, Juan Jose ^b   Domingo, Gonzalo J ^a  

^a PATH   (United States)

^b PATH   (Nicaragua)

^c Centro Nacional de Diagnástico y Referencia   (Nicaragua)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; FOOD; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MEDICAL INFORMATION; NICARAGUA; PATIENT CARE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; TRAFFIC AND TRANSPORT; VIRUS LOAD; COST; COST OF ILLNESS; DRUG MONITORING; ECONOMICS; HEALTH CARE PLANNING; LABORATORY; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; COST OF ILLNESS; COSTS AND COST ANALYSIS; DRUG MONITORING; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; LABORATORIES; NICARAGUA; PREVALENCE; VIRAL LOAD;

EID: 78049408570     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-43     Document Type: Article

References (29)

1. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. SJ Goldie Y Yazdanpanah EE Losina MC Weinstein X Anglaret RP Walensky HE Hsu A Kimmel C Holmes JE Kaplan KA Freedberg, N Engl J Med 2006 355 11 1141 1153 10.1056/NEJMsa060247 16971720
2. Expanding antiretroviral options in resource-limited settings - a cost-effectiveness analysis. E Bendavid R Wood DA Katzenstein AM Bayoumi DK Owens, J Acquir Immune Defic Syndr 2009 52 1 106 113 10.1097/QAI. 0b013e3181a4f9c4 19448557
3. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. D Bishai A Colchero DT Durack, AIDS 2007 21 10 1333 1340 10.1097/QAD.0b013e328137709e 17545710
4. Cost-effectiveness of highly active antiretroviral therapy in South Africa. M Badri G Maartens S Mandalia LG Bekker JR Penrod RW Platt R Wood EJ Beck, PLoS Med 2006 3 1 4 10.1371/journal.pmed.0030004 16318413
5. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. AD Kimmel MC Weinstein X Anglaret SJ Goldie E Losina Y Yazdanpanah E Messou KL Cotich RP Walensky KA Freedberg, J Acquir Immune Defic Syndr 2010 54 3 258 268 10.1097/QAI.0b013e3181d0db97 20404739
6. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. RP Walensky AL Ciaranello JE Park KA Freedberg, Clin Infect Dis 2010 51 1 85 92 10.1086/653119 20482371
7. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. M Badri SD Lawn R Wood, BMC Infect Dis 2008 8 89 10.1186/1471-2334-8-89 18601727
8. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. R Kantor L Diero A Delong L Kamle S Muyonga F Mambo E Walumbe W Emonyi P Chan EJ Carter J Hogan N Buziba, Clin Infect Dis 2009 49 3 454 462 10.1086/600396 19569972
9. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. FK Sawe JA McIntyre, Clin Infect Dis 2009 49 3 463 465 10.1086/600397 19569971
10. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. RK Gupta A Hill AW Sawyer A Cozzi-Lepri V von Wyl S Yerly VD Lima HF Gunthard C Gilks D Pillay, Lancet Infect Dis 2009 9 7 409 417 10.1016/S1473-3099(09)70136-7 19555900
11. HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep/TaqMan test. T Elbeik R Dalessandro RA Loftus S Beringer, Expert Rev Mol Diagn 2007 7 6 723 753 10.1586/14737159.7.6.723 18020903
12. Cost assessment of the automated VERSANT 440 Molecular System versus the semi-automated System 340 bDNA Analyzer platforms. T Elbeik RA Loftus S Beringer, Expert Rev Mol Diagn 2007 7 6 713 722 10.1586/14737159.7.6.713 18020902
13. Global cost modeling analysis of HIV-1 and HCV viral load assays. T Elbeik YM Chen SV Soutchkov RA Loftus S Beringer, Expert Rev Pharmacoecon Outcomes Res 2003 3 4 383 407 10.1586/14737167.3.4.383 19807450
14. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. F Rouet DK Ekouevi ML Chaix M Burgard A Inwoley TD Tony C Danel X Anglaret V Leroy P Msellati F Dabis C Rouzioux, J Clin Microbiol 2005 43 6 2709 2717 10.1128/JCM.43.6.2709-2717.2005 15956387
15. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow reliability, and direct costs. CR Sloma JJ Germer TM Gerads JN Mandrekar PS Mitchell JD Yao, J Clin Microbiol 2009 47 4 889 895 10.1128/JCM.02231-08 19193837
16. Epidemiological Fact Sheet on HIV and AIDS. http://apps.who.int/ globalatlas/predefinedReports/EFS2008/full/EFS2008-NI.pdf
17. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. B Amuron G Namara J Birungi C Nabiryo J Levin H Grosskurth A Coutinho S Jaffar, BMC Public Health 2009 9 290 10.1186/1471-2458-9-290 19671185
18. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. CM Miller M Ketlhapile H Rybasack-Smith S Rosen, Trop Med Int Health 2010 15 Suppl 1 48 54 10.1111/j.1365-3156.2010.02514. x 20586960
19. Barriers to access to antiretroviral treatment in developing countries: a review. M Posse F Meheus H van Asten A van der Ven R Baltussen, Trop Med Int Health 2008 13 7 904 913 10.1111/j.1365-3156.2008.02091.x 18466183
20. Challenges in implementing CD4 testing in resource-limited settings. T Peter A Badrichani E Wu R Freeman B Ncube F Ariki J Daily Y Shimada M Murtagh, Cytometry B Clin Cytom 2008 74 Suppl 1 123 S130 18348208
21. Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes. The Kesho Bora preparatory Study. F Rouet V Foulongne J Viljoen K Steegen P Becquart D Valea S Danaviah M Segondy C Verhofstede P Van de Perre, J Virol Methods 2009 163 2 253 257 10.1016/j.jviromet.2009.10.005 19837114
22. Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. W Labbett A Garcia-Diaz Z Fox GS Clewley T Fernandez M Johnson AM Geretti, J Clin Microbiol 2009 47 10 3266 3270 10.1128/JCM.00715-09 19656978
23. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. M Mine K Bedi T Maruta D Madziva M Tau T Zana T Gaolathe S Moyo K Seipone N Ndwapi M Essex R Marlink, J Virol Methods 2009 159 1 93 97 10.1016/j.jviromet.2009.03.008 19442851
24. Quantifying HIV for Monitoring Antiretroviral Therapy in Resource-Poor Settings. WS Stevens LE Scott SM Crowe, The Journal of Infectious Diseases 2010 201 s1 16 S26 10.1086/650392 20225942
25. A rapid and automated sample-to-result HIV load test for near-patient application. S Tanriverdi L Chen S Chen, J Infect Dis 2010 201 Suppl 1 52 S58 10.1086/650387 20225947
26. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. A Johannessen C Garrido N Zahonero L Sandvik E Naman SL Kivuyo MJ Kasubi SG Gundersen JN Bruun C de Mendoza, Clin Infect Dis 2009 49 6 976 981 10.1086/605502 19663598
27. Increased Access to Diagnostic Tests for HIV Case Management. JL Gerlach D Boyle GJ Domingo BH Weigl M Free, aids2031 2008 http://www.aids2031.org/ working-groups/science-and-technology?view=papers#45
28. Laboratory Operations, Specimen Processing, and Handling for Viral Load Testing and Surveillance. A Puren JL Gerlach BH Weigl DM Kelso GJ Domingo, The Journal of Infectious Diseases 2010 201 s1 27 S36 10.1086/650390 20225943
29. Challenges for Rapid Molecular HIV Diagnostics. ML Schito MP D'Souza SM Owen MP Busch, The Journal of Infectious Diseases 2010 201 s1 1 S6 10.1086/650394 20225941